证券代码：688607 证券简称：康众医疗 公告编号：2025-030 江苏康众数字医疗科技股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东会召开日期：2025年8月1日 ? 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、 召开会议的基本情况 （一） 股东会类型和届次 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 8 月 1 日 14 点 30 分 召开地点：苏州工业园区星湖街 218 号生物纳米园 B3 楼 501 室公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 8 月 1 日 至2025 年 8 月 1 日 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易 ...

江苏康众数字医疗科技股份有限公司 重大经营与投资决策管理制度 第一章 总则 第一条 为了规范江苏康众数字医疗科技股份有限公司（以下简称"公司"） 重大经营及对外投资决策程序，建立系统完善的重大经营及对外投资决策机制， 确保决策的科学、规范、透明，有效防范各种风险，保障公司和股东的利益，根 据有关法律、法规及《江苏康众数字医疗科技股份有限公司章程》 （以下简称"《公 司章程》"）的规定，特制定本制度。 第二条 重大经营与投资决策管理的原则：遵循合法、审慎、安全、有效的 原则，控制投资风险、注重投资效益。 第三条 重大投资项目的发起人应当负责对该项目的可行性、投资风险、投 资回报等事宜进行专门研究和评估，监督重大投资项目的执行进展，如发现投资 项目出现异常情况，应及时向公司总经理办公会或董事会报告。 第二章 决策范围 第四条 本制度所指的重大经营事项包括： （一）重大融资事项； （二）签订重大购买、购销合同的事项； （三）公司购买或处置固定资产的事项； （四）公司总经理办公会、董事会、股东会制定的对公司生产经营具有重大 影响的其他事项。 第五条 本制度所指的投资事项包括： （一）购买或出售资产（不包括购买原材料、 ...

江苏康众数字医疗科技股份有限公司 总经理工作细则 江苏康众数字医疗科技股份有限公司 总经理工作细则 第一章 总则 第一条 江苏康众数字医疗科技股份有限公司（以下简称"公司"）为完善 公司法人治理结构，明确总经理的职责、规范总经理行使职权，促进公司稳定健 康发展，根据《中华人民共和国公司法》（以下简称"《公司法》"）等相关法律、 法规和规范性文件及《江苏康众数字医疗科技股份有限公司章程》 （以下简称"《公 司章程》"）的规定，特制定本细则。 第二条 总经理履行职权时，应当遵守有关法律、法规、规范性文件、《公 司章程》以及本细则的规定。 第二章 总经理的任职资格与任免程序 第三条 总经理应当具备下列任职条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营 管理能力； （二）具有调动员工积极性、建立合理的组织机构、协调各方面内外关系和 统揽全局的能力； （三）具有一定年限的企业管理工作经历，精通业务，熟悉商业领域经营业 务和掌握国家有关政策、法律、法规； （四）诚信勤勉、廉洁奉公、正直公道； （五）精力充沛，有较强的使命感和积极开拓的进取精神。 第四条 《公司法》《公司章程》或相关法规规定的不 ...

Group 1 - The core viewpoint is that AI and digitalization are reshaping the global healthcare system, with digital healthcare being the future of medical health [1][2] - Yuan Yi Capital, established in 2016, focuses on early-stage investments in digital healthcare technology, having invested in over 70 companies with a total management scale exceeding 30 billion RMB [1][2] - The 2024 China Digital Healthcare Innovation Development Blue Book indicates that digital healthcare is an emerging field created by the integration of digital technology and medical scenarios, optimizing the entire diagnostic process [2][3] Group 2 - In the U.S. market, digital healthcare is a mainstream investment area, with AI and digitalization-related projects accounting for 50% of the top 100 financing deals in 2024 [3] - The evolution of medical models is driven by technology, transitioning from reliance on doctors' experience to data-driven personalized treatment and comprehensive management [3][5] - The rapid development of digital healthcare is attributed to the inefficiencies in the current healthcare system, which leads to insufficient supply and rising costs [3][5] Group 3 - Generative AI is seen as a golden opportunity in the healthcare sector due to strong demand, a large market, and high barriers to entry [5][6] - Generative AI can enhance various aspects of the healthcare ecosystem, including improving diagnostic efficiency for doctors and transforming hospital management [5][6] - A survey indicates that 90% of doctors find AI tools trustworthy, with over half willing to inform patients about AI's involvement in their treatment [6] Group 4 - Yuan Yi Capital identifies two types of innovative opportunities brought by generative AI: infrastructure development for traditional sectors and specialized AI applications in specific disease areas [6] - The focus on specialized AI applications is seen as a trillion-scale new market that can drive high-quality, low-cost personalized medical services [6]

Core Viewpoint - Health 160 International Limited is seeking to list on the Hong Kong Stock Exchange, but faces significant challenges including weak profitability and growth bottlenecks [1][2][3] Group 1: Company Overview - Health 160 was established in 2005 and aims to be the largest digital healthcare service platform in China by 2024, based on various metrics [1] - The company has attempted to list on the Hong Kong Stock Exchange three times since December 2023 without success [1] Group 2: Revenue Structure - Health 160's revenue is primarily derived from two segments: pharmaceutical sales and digital healthcare solutions, with pharmaceutical sales accounting for 73.2%, 71.7%, and 68.7% of total revenue from 2022 to 2024 [2][3] - The gross margin for pharmaceutical sales has significantly declined from 7.9% in 2020 to 1.4% in 2024, which is substantially lower than industry averages [3][4] Group 3: Financial Performance - Revenue from pharmaceutical sales for 2022, 2023, and 2024 was 385 million, 451 million, and 427 million respectively, with gross profits of 15.65 million, 8.75 million, and 6.15 million [3] - The company has reported operating losses of 79 million, 100 million, and 105 million from 2022 to 2024, indicating ongoing financial struggles [10] Group 4: Customer Dependency - The company has a high dependency on a few major clients, with revenue from the top five clients accounting for 41.3%, 34.6%, and 40.0% of total revenue from 2022 to 2024 [5] - The largest client, Henan Pengyuan Pharmaceutical Co., Ltd., has raised concerns due to reported debt issues despite significant procurement from Health 160 [5] Group 5: Digital Healthcare Solutions - The digital healthcare segment includes appointment scheduling, content marketing, and IT services, but lacks differentiation and competitive advantage [6][7] - Revenue from digital healthcare solutions has shown growth but at a slowing rate, with 2022, 2023, and 2024 revenues of 141 million, 178 million, and 194 million respectively [6] Group 6: User Engagement - Average monthly active users have stagnated, with figures of 3.9 million, 3.3 million, 3.1 million, and 3.3 million from 2021 to 2024, indicating a growth bottleneck [8][9] - The user repurchase rate has decreased to 65.7%, the lowest in three years [9] Group 7: Sales and Marketing Expenses - Sales expenses have increased consistently from 82 million in 2021 to 117 million in 2024, with a sales expense ratio reaching a historical high of 18.9% in 2024 [10]

关于诉讼前景，专业人士均认为，法院可能允许案件继续审理，即使礼来当前的主张存在瑕疵，也可能 通过修正后重新提起诉讼。专家指出，礼来在佛罗里达州提起的诉讼中，关于配药公司贬低其品牌形象 的主张可能最具胜算。此外，专家还提到，FDA于6月26日更新了禁止配药清单，但GLP-1类药物未被 列入，这可能成为配药公司反驳礼来"越权指控"的有力证据。 大摩强调，目前礼来和诺和诺德尚未对配药公司提起专利侵权诉讼，但专家普遍认为，专利侵权诉讼未 来仍有可能发生。由于专利侵权属于严格责任范畴，配药公司难以证明其使用司美格鲁肽(semaglutide) 或替尔泊肽(tirzepatide)未构成侵权。一旦败诉，配药公司可能面临高达三倍赔偿的惩罚性赔偿。 在估值方面，大摩给予Hims的目标价基于2026年营收预期的3倍市销率(EV/S)，以及0.08倍的市销率增 长率(EV/S/G)。该行认为，相较于其他数字健康和直接面向消费者(DTC)医疗公司，这一估值存在一定 折价，但也反映出公司当前面临的不确定性风险。 大摩指出，Hims未来面临的主要上行风险包括：用户增长超预期、成功拓展减肥和激素替代疗法(HRT) 等高潜力市场，以及平台 ...

Core Insights - The healthcare industry is experiencing significant developments in the first half of 2025, with companies like "Health 160" and "Weimai" filing for IPOs, while others like "Good Mood" and "Weimai" secure substantial financing [1][4][9]. Company Summaries - "Health 160" has faced cash flow challenges, with negative operating cash flow for four consecutive years and only 46.11 million RMB in cash against 70.2 million RMB in debts due within 90 days. The company's revenue heavily relies on low-margin drug sales, which account for over 70% of its income, resulting in a gross margin of only 1.9% [5]. - "Weimai" has submitted its prospectus for a main board listing, reporting revenues of 512 million RMB, 627 million RMB, and 653 million RMB from 2022 to 2024, with gross margins increasing from 17.2% to 19.9% during the same period. However, the company has also reported significant losses, with adjusted net losses narrowing from 4.14 billion RMB in 2022 to 1.93 billion RMB in 2024 [6][8]. - "Good Mood," an internet psychological healthcare platform, completed a financing round of several hundred million RMB, with investments from institutions like CITIC Medical Fund and Xu Zhou Industrial Investment [9][10]. - "Lingjian" announced an E-round financing of several hundred million RMB, backed by Wuxi Venture Capital Group and Binhu Industrial Group, focusing on providing services to over 50,000 dental and medical beauty institutions [11][12]. Industry Trends - The digital health sector is evolving with AI integration, as seen in partnerships like that of "Weimai" and Alibaba Cloud, aiming to build a comprehensive AI healthcare infrastructure [15][17]. - The launch of "Ping An Chip Doctor" by Ping An Health represents a significant innovation in AI-driven healthcare services, enhancing accessibility and efficiency in patient interactions [24][26]. - The introduction of AI applications like "Anzheng Er," which combines advanced reasoning capabilities with healthcare services, indicates a trend towards more personalized and efficient patient care [26][27]. - The healthcare landscape is shifting towards a more integrated model, with companies like Meituan Health and JD Health leveraging AI to create comprehensive service ecosystems that connect online and offline healthcare services [20][22].

Group 1 - The core risk of the company lies in the mismatch between its "digital healthcare facade" and "pharmaceutical wholesale core," revealing structural vulnerabilities in its business model [2] - The majority of revenue is derived from low-margin wholesale sales of pharmaceutical health products, with a shrinking proportion of high-margin digital healthcare solutions, leading to a negative cash flow situation [2] - The company has experienced continuous negative operating cash flow for four years due to high inventory costs, which consume 90% of sales and service costs [2] Group 2 - User engagement has deteriorated, with average monthly active users dropping from 3.9 million in 2021 to 3 million in 2024, indicating a decline in platform attractiveness [3] - Cumulative losses over three and a half years amount to 460 million yuan, with losses expanding to 83.26 million yuan in the first half of 2024 [4] - The IPO represents a race against time for the company, focusing on whether it can attract investors with its "largest digital healthcare platform" narrative and whether it can transform its user base into high-margin digital service revenue [4]

舒毕磊介绍，下一步，朝阳区将重点推进聚焦"AI+精准诊疗"打造区域品牌；贯通成果转化全链条，推 动基础研究、应用研究与概念验证融合发展；加快重大平台和空间布局，持续优化创新生态，为数字医 疗产业高质量发展提供有力支撑，携手各界共建"健康中国"。 本次大会以"医智共振，双擎跃迁"为主题，系统呈现"AI医疗健康"在重大平台、创新应用、协同生态等 关键领域的前沿成果与机制创新，深入探讨政策机制、专病路径、数据资产等关键议题。 数据显示，医药健康产业已经成为北京重要经济产业支柱之一，去年整体规模达到1.6万亿元，首次突 破万亿元。北京市积极推动医药产业与人工智能深度融合，加快智慧医疗创新与转化应用。 新京报贝壳财经讯(记者丁爽)"朝阳区全力推动数字医疗产业发展，围绕体制机制建设，建立了'三医'协 同部门和数字医疗推进专班，从场景开放、平台建设等方面开展顶层设计和产业培育；围绕场景开放， 以专病为抓手，推动落地应用；围绕成果转化，以概念验证项目为抓手，推动生态协同服务支撑。"7月 5日，2025中国数字医疗大会(CDHC)暨第二届朝阳区数字医疗产业发展论坛上，北京市朝阳区委常委、 副区长舒毕磊在致辞中表示。 4月7日， ...

Core Insights - The article highlights the transformation of healthcare and transportation services in Beijing through digital technology, improving user experience and operational efficiency [1][4]. Healthcare Sector - The Beijing appointment registration platform allows users to easily book appointments at 299 hospitals, check imaging reports online, and conduct follow-up consultations [1]. - Since its launch, the platform has served over 20 million users and provided 150 million outpatient services, with a 25% increase in primary care visits and a 20% reduction in idle appointment slots [4]. - The implementation of an AI model to combat scalping has led to the banning of 70,000 accounts, a 10% decrease in patient complaints, and a satisfaction rate exceeding 95% [4]. Transportation Sector - The article describes the integration of autonomous vehicles in Beijing's demonstration area, supported by a "vehicle-road-cloud" application that enhances the safety and efficiency of transportation [4]. - Smart traffic lights equipped with sensors can adjust their timing based on real-time traffic data, optimizing traffic flow and increasing vehicle speed [5]. - Over 1,000 smart intersections exist in the demonstration area, with the information control platform optimizing traffic light timing up to 35,000 times daily, resulting in improved road capacity [5]. Recognition and Future Outlook - Both the healthcare appointment platform and the vehicle-road-cloud application were recognized as "Top Ten Benchmark Applications" at the 2025 Global Digital Economy Conference, emphasizing their technological leadership and human-centered approach [5].